<DOC>
	<DOC>NCT02331680</DOC>
	<brief_summary>This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration and who have daily urine volume of at least 500 mL/day.</brief_summary>
	<brief_title>A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Chronic renal failure requiring hemodialysis or hemodiafiltration 3 times a week Daily urine volume of â‰¥ 500 mL/day Male or female patients age 20 to 80 years, inclusive Use of one of the specified contraceptive methods until 4 weeks after final IMP administration Capable of providing their own written informed consent prior to any trialrelated procedures being performed Patients with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause Patients with NYHA class IV heart failure Patients with impaired hepatic function(chronic hepatitis, druginduced liver injury) Patients with serious ischemic heart disease who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial Patients with serious arrhythmia who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial Patients with serious secondary hyperparathyroidism(intact parathyroid hormone &gt; 500 pg/mL) Patients who are concomitantly undergoing peritoneal dialysis Patients with a history of cerebrovascular disease or coronary artery disease within 4 weeks prior to informed consent, a history of hypersensitivity to any ingredient of tolvaptan or benzazepine derivatives such as mozavaptan hydrochloride or a history of impaired hepatic function(chronic hepatitis, druginduced liver injury) Patients with any of the following abnormal laboratory values: hemoglobin &lt; 8.0 g/dL, total bilirubin &gt; 3.0 mg/dL, ALT (GPT) or AST (GOT) &gt; 2 times the upper limit of the reference range, serum sodium &gt; upper limit of the reference range, serum sodium &lt; 125 mEq/L, or serum potassium &gt; 6.0 mEq/L Patients who are unable to sense thirst or who have difficulty with fluid intake Patients who have received OPC41061 in history. Participation in any other clinical trial or postmarketing clinical study within 4 weeks prior to informed consent for the present trial Female patients who are pregnant, possibly pregnant, or nursing Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Undergoing Hemodialysis</keyword>
	<keyword>Undergoing Hemodiafiltration</keyword>
</DOC>